Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
In the present project the investigators will evaluate whether glucagonotropic properties of the gut‐derived incretin hormone glucose‐dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.
Epistemonikos ID: 9857574f0e764d185d85116d67db93e32818625e
First added on: May 21, 2024